A research study of a new combination antibiotic is now underway for people suffering from Crohn’s disease.
Doctors are seeking participants for a clinical study testing a novel approach for the treatment of Crohn’s disease: treating the bacteria which may be a cause of Crohn’s disease.
The study medication is in pill form and is a combination of three antibiotics: clarithromycin, rifabutin, and clofazimine. Remission at week 26 is the primary objective of the study; however, the study duration is approximately 60 weeks.
In order to participate, you must be diagnosed with Crohn’s disease for longer than six months and be 18 to 75 years old.
Other criteria may apply.